Education
About Us
Working with TipRanks
Follow Us
Prime Medicine, Inc. (PRME)
NASDAQ:PRME
PRME Analyst Ratings
Moderate Buy
3 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PRME Stock 12 Month Forecast
Average Price Target
$6.08
▲(82.58% Upside)
| Highest Price Target$9.00 | Average Price Target$6.08 | Lowest Price Target$4.25 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
―
Hold
―
Reiterated
11/13/25
Citi
$5→$4.25
Hold
27.63%
Upside
Reiterated
11/11/25
JonesTrading
$5
Buy
50.15%
Upside
Reiterated
11/11/25
Chardan Capital
$9
Buy
170.27%
Upside
Reiterated
11/09/25
RATING
Buy
PRICE TARGET
$9.00
Updating our model for 3Q25 financials including updated dilution information for Prime's July offering brings our PT to $9.
TD Cowen
―
Buy
―
Reiterated
11/07/25
Wall Street Analysts Are Bullish on Top Healthcare PicksWe continue to view PRME as a leader in the gene editing space and see shares as undervalued for the potential of the prime editing platform With respect to PRME's lead in-vivo program for Wilson's disease (PM577), the company noted that it remains on track to produce initial clinical data from the program in 2027. Prime has guided that it could file an IND and/or CTA for the program in H1:26, and will discuss the company's strategy in the space at a company-hosted KOL event on November 12. We look forward to additional color around the company's plans on the call (as well as new preclinical mouse data for PM577 at AASLD this weekend), and note that Prime has indicated that >20k patients suffer from Wilson's disease in the U.S./Europe.
Guggenheim
$18→$5
Buy
50.15%
Upside
Reiterated
08/13/25
Morgan Stanley
―
Hold
―
Reiterated
08/11/25
PRME.O Prime Medicine Inc Equal-Weight; Price target initiated at 3.79.
Citizens JMP
$6
Buy
80.18%
Upside
Reiterated
06/18/25
Jefferies
$13→$9
Buy
170.27%
Upside
Reiterated
05/19/25
J.P. Morgan
―
Hold
―
Downgraded
05/19/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
―
Hold
―
Reiterated
11/13/25
Citi
$5→$4.25
Hold
27.63%
Upside
Reiterated
11/11/25
JonesTrading
$5
Buy
50.15%
Upside
Reiterated
11/11/25
Chardan Capital
$9
Buy
170.27%
Upside
Reiterated
11/09/25
RATING
Buy
PRICE TARGET
$9.00
Updating our model for 3Q25 financials including updated dilution information for Prime's July offering brings our PT to $9.
TD Cowen
―
Buy
―
Reiterated
11/07/25
Wall Street Analysts Are Bullish on Top Healthcare PicksWe continue to view PRME as a leader in the gene editing space and see shares as undervalued for the potential of the prime editing platform With respect to PRME's lead in-vivo program for Wilson's disease (PM577), the company noted that it remains on track to produce initial clinical data from the program in 2027. Prime has guided that it could file an IND and/or CTA for the program in H1:26, and will discuss the company's strategy in the space at a company-hosted KOL event on November 12. We look forward to additional color around the company's plans on the call (as well as new preclinical mouse data for PM577 at AASLD this weekend), and note that Prime has indicated that >20k patients suffer from Wilson's disease in the U.S./Europe.
Guggenheim
$18→$5
Buy
50.15%
Upside
Reiterated
08/13/25
Morgan Stanley
―
Hold
―
Reiterated
08/11/25
PRME.O Prime Medicine Inc Equal-Weight; Price target initiated at 3.79.
Citizens JMP
$6
Buy
80.18%
Upside
Reiterated
06/18/25
Jefferies
$13→$9
Buy
170.27%
Upside
Reiterated
05/19/25
J.P. Morgan
―
Hold
―
Downgraded
05/19/25
Best Analysts Covering Prime Medicine, Inc.
1 Month
xxx
Success Rate
3/7 ratings generated profit
Average Return
-6.47%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 42.86% of your transactions generating a profit, with an average return of -6.47% per trade.
3 Months
xxx
Success Rate
4/8 ratings generated profit
Average Return
+44.42%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +44.42% per trade.
1 Year
Success Rate
8/8 ratings generated profit
Average Return
+80.29%
reiterated a buy rating 4 days ago
Copying Soumit Roy's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +80.29% per trade.
2 Years
xxx
Success Rate
8/8 ratings generated profit
Average Return
+76.31%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +76.31% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
PRME Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
9
4
2
1
0
Buy
2
4
4
3
2
Hold
6
4
5
6
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
12
11
10
7
Each month's total comprises the sum of three months' worth of ratings.
PRME Financial Forecast
PRME Stock Forecast FAQ
What is PRME’s average 12-month price target, according to analysts?
Based on analyst ratings, Prime Medicine, Inc.’s 12-month average price target is 6.08.
What is PRME’s upside potential, based on the analysts’ average price target?
Prime Medicine, Inc. has 82.58% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PRME a Buy, Sell or Hold?
Prime Medicine, Inc. has a consensus rating of Moderate Buy which is based on 3 buy ratings, 2 hold ratings and 0 sell ratings.
What is Prime Medicine, Inc.’s price target?
The average price target for Prime Medicine, Inc. is 6.08. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $9.00 ,the lowest forecast is $4.25. The average price target represents 82.58% Increase from the current price of $3.33.
The highest analyst price target is $9.00 ,the lowest forecast is $4.25. The average price target represents 82.58% Increase from the current price of $3.33.
What do analysts say about Prime Medicine, Inc.?
Prime Medicine, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of PRME?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.